β3肾上腺素能受体(β3AR)是继β1、β2肾上腺素能受体后又发现的一种β肾上腺素能受体。临床调查结果表明,2型糖尿病并发心功能不全的发病率和死亡率明显高于一般人群,是非糖尿病患者的4～8倍[1]。近年来对β3AR在糖尿病及心力衰竭中的研究表明,β3AR激动剂有一定的抗糖尿病作用;在心力衰竭早期产生心肌保护作用,但在心力衰竭晚期则出现促进心力衰竭发展的作用。 β3 adrenergic receptor (β3AR) is a beta-adrenergic receptor found after β1, β2 adrenergic receptors. Clinical findings show that the incidence and mortality of type 2 diabetes complicated with cardiac insufficiency were significantly higher than those of the general population, which were 4 to 8 times higher than those of non-diabetic patients [1]. In recent years, the study of β3AR in diabetes and heart failure showed that β3AR agonist has certain anti-diabetic effect; it has cardioprotective effect in the early stage of heart failure, but promotes the development of heart failure in later stage of heart failure.